1. Home
  2. Earnings Beat
  3. 534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations

534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations

4
0

Innocan Pharma Corporation (OTCQB:INNPF) (CSE:INNO) (FSE: IP4), a cannabinoids-focused pharmaceutical company based in Israel, announced Monday its financial results for the the year ended December 31, 2023. The company reported a nearly sixfold increase in its revenues, reaching US$13.7 million, primarily fueled by the sales performance of its subsidiary, BI Sky Global Ltd.

Full Year 2023 Financial Highlights

  • Revenues increased 534% year-over-year to US$13.7 million, compared to US$2.6 million in 2022.
  • Operating loss decreased by 61% to US$3.8 million in 2023, compared to US$6.3 in 2022.
  • Adjusted EBITDA: 
  • Gross profit increased 568% year-over-year to US$12.0 million, compared to US$2.1 million for 2022.
  • The Company completed a $1.5 million capital raise in March 2024.

Top executives from leading cannabis operators are slated to share valuable insights at the upcoming Benzinga Cannabis Capital Conference in Florida on April 16-17. The two-day event that returns to The Diplomat Beach Resort will …

Full story available on Benzinga.com

Visited 4 times, 1 visit(s) today